SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEO is heavily discussed currently, driven by a mix of political factors and immigration-related news. Community members are highlighting potential policy impacts and contract opportunities. Sentiment is divided, with some seeing long-term value and others expressing strong ethical concerns.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is trending as traders discuss the potential for a rebound amid fluctuating weather forecasts and debate whether natural gas prices are already reflecting winter demand; the community is actively analyzing technical indicators and storage data, while considering factors like LNG exports and production levels to gauge future price movements.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

FRMI is experiencing significant volatility as investors debate its future as an energy provider for data centers, particularly after a canceled funding agreement; the stock saw a sharp decline but is now recovering. Community discussion centers on political connections, potential new tenants (including speculation around big tech partnerships), and the company's ambitious plans in the Texas energy market. Despite some skepticism about its current financials, the stock continues to generate buzz due to its unique position and the growing demand for AI infrastructure.

Anheuser-Busch InBev SA/NV operates as a holding company, which engages in the manufacture and distribution of alcoholic and non-alcoholic beverages. It operates through the following geographical segments: North America, Middle Americas, South America, EMEA, Asia Pacific, and Global Export and Holding Companies. The company was founded on August 2, 1977 and is headquartered in Leuven, Belgium.

Anheuser-Busch InBev SA/NV - ADR

Anheuser-Busch InBev

BUD is trending amid discussions about market share, marketing strategies, and potential acquisitions. Community members are debating the impact of past controversies on the brand's value, while others highlight its global presence and potential for long-term growth, as well as short-term upside. Recent news includes Wells Fargo adjusting its rating to Overweight, and Tilray acquiring eight beer and beverage brands from Anheuser-Busch InBev.

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Immunome Inc

Immunome ($IMNM) is trending amid discussions about its pipeline and recent business development, including collaborations focused on antibody-drug conjugates (ADCs). Community members are weighing the potential impact of upcoming Phase 3 data and comparing it to existing treatments, while also noting new job postings and insider activity. Overall, investors are focused on Immunome's long-term prospects in the oncology space and potential for growth.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry ($BB.TSX) is trending as investors analyze the potential impact of upcoming earnings and partnerships, especially regarding QNX technology. Bullish sentiment is fueled by optimism around QNX's expanding role in automotive and IoT, with community members closely watching technical indicators and revenue potential. Discussions also involve institutional investment trends and potential market catalysts.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics ($KYTX) is trending due to anticipation surrounding Phase 2 data for its KYV-101 trial in stiff person syndrome, expected soon, with the community actively discussing potential positive results. Investors are weighing the risk/reward, referencing a Morgan Stanley report with an increased price target based on a favorable risk profile. Some traders note call option activity and potential early knowledge of the upcoming data release.

Equinox Gold Corp. is a growth-focused mining company, which engages in the exploration of gold mining properties. It operates through the following segments: Greenstone, Mesquite, Castle Mountain, Los Filos, Aurizona, Fazenda, RDM, Santa Luz, and Corporate. The company was founded by Marc Pais on March 23, 2007, and is headquartered in Vancouver, Canada.

Equinox Gold Corp

Equinox Gold is trending amid news of selling its Brazil operations to focus on North American growth. The community is discussing the potential 10%+ move, options activity indicating upside, and a C$24.00 price target announced by Stifel Nicolaus, while also mentioning its relation to gold prices and potential.

ONDO is a DeFi primitive that enables users to originate risk-isolated, fixed yield loans backed by yield-generating crypto-assets. It's unique because it's a permissionless protocol that allows users to interact on a peer-to-pool basis with no intermediaries.

Ondo

Ondo is trending as it gears up to launch tokenized U.S. stocks and ETFs on Ethereum, potentially bridging traditional finance with DeFi; the community anticipates this launch, while some express concerns about token unlocks and its effect on price. Many view it as undervalued, especially given its connection to BlackRock and potential in the Real World Asset (RWA) space, while others remain skeptical about the token's direct utility.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox (RBLX) is trending amidst analyst activity, with community members discussing a recent downgrade from JPMorgan and a new Buy rating from B. Riley, highlighting differing perspectives on the stock's future. Community members are actively debating the company's profitability, growth prospects, and potential risks related to user safety and regulatory scrutiny, especially as it relates to market conditions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company reported Q4 adjusted earnings per share of $1.95, above a Wall Street estimate of $1.87, according to data from Fiscal AI.&nbsp;</li><li>The company now expects $19.1 billion in sales in the first quarter of fiscal year 2026, above an analyst estimate of $18.3 billion.&nbsp;</li><li>Broadcom, like Nvidia, has greatly benefited from the AI boom with its abilities in designing custom AI chips.</li></ul> Shares of Broadcom Inc (AVGO) rose 2.3% after hours on Thursday after the company reported fourth quarter (Q4) earnings that beat Wall Street expectations and issued an upbeat outlook for the first quarter of 2026.The company reported Q4 adjusted earnings per share of $1.95, above a Wall Street estimate of $1.87, according to data from Fiscal AI.Revenue for the three months came in at $18.02 billion, marking a growth of 28% year-over-year, and above an analyst estimate of $17.46 billion.<h2 class="st-heading-2">Q1 2026 Forecast</h2>The company now expects $19.1 billion in sales in the first quarter of fiscal year 2026, above an analyst estimate of $18.3 billion, on the back of strong AI chip and semiconductor demand."We see the momentum continuing in Q1 and expect AI semiconductor revenue to double year-over-year to $8.2 billion, driven by custom AI accelerators and Ethernet AI switches,” CEO Hock Tan said in a statement. The company further expects first quarter core profit to be 67% of projected revenue.However, in the non-AI semiconductor segment, the company expects revenue to be about $4.1 billion in the quarter, flat from a year ago. “Directionally, we expect AI revenue to continue to accelerate and drive most of our growth, and non-AI semiconductor revenue to be stable,” the CEO said.<h2 class="st-heading-2">AI Boom Aids Stock Rally</h2>Broadcom, like Nvidia, has greatly benefited from the AI boom with its abilities in designing custom AI chips. AVGO stock has gained over 75% this year and by about 122% over the past 12 months.Tan said on Thursday that the company now has about $73 billion in AI backlog, almost half of the company’s consolidated backlog of $162 billion. The company expects to deliver the AI backlog over the next 18 months.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AVGO">AVGO stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user sounded optimistic about the stock hitting $500 in Friday trading.<stembedurl>https://stocktwits.com/buyacramer/message/638934302</stembedurl>Another sounded hopes for a Microsoft partnership.<stembedurl>https://stocktwits.com/bestest1/message/638934125</stembedurl>The company inked a partnership with OpenAI in October to develop custom chips.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/costco-stock-dips-after-hours-despite-strong-q1-holiday-momentum/cLIxATXREF4">Costco Stock Dips After Hours Despite Strong Q1 And Holiday Momentum — Retail Bulls Eye Rally Next Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

The Broadcom Ink logo is displayed on a mobile phone in this photo illustration in Brussels, Belgium, on September 2, 2025. 

Broadcom Stock Jumps After Hours As Strong Q4 And Surging AI Chip Demand Drive Upbeat Outlook

The company now expects $19.1 billion in sales in the first quarter of fiscal year 2026, above an analyst estimate of $18.3 billion on the back of strong AI chip demand. 

Equity

The company now expects $19.1 billion in sales in the first quarter of fiscal year 2026, above an analyst estimate of $18.3 billion on the back of strong AI chip demand. 


<ul class="summary-bullets"><li>The company said that reduction in body mass index as well as hyperphagia or extreme, insatiable, or excessive hunger that does not go away after eating was observed at month 3 and month 6 in the trial.</li><li>The company said that the results are supportive of a late-stage registrational trial.&nbsp;</li><li>Bank of America subsequently raised its price target on Rhythm to $140 from $127 while keeping a ‘Buy’ rating on the shares.</li></ul>Shares of Rhythm Pharmaceuticals, Inc. (RYTM) jumped 14% on Thursday after the company announced that its mid-stage study evaluating Setmelanotide in Prader-Willi Syndrome patients showed reduction in weight and hyperphagia.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-preliminary-data-exploratory">said</a> that the reduction in body mass index as well as hyperphagia or extreme, insatiable, or excessive hunger that does not go away after eating was observed at the third and sixth-month mark in the trial. The company said that the results are supportive of a late-stage registrational trial.<h2 class="st-heading-2">Trial Design</h2>The company enrolled 18 patients with Prader-Willi Syndrome (PWS) in the ongoing 52 week trial. Of this, 17 patients remain enrolled on active Setmelanotide therapy and the company will share additional data in the first half of 2026, it added.PWS is a rare genetic disorder requiring lifelong management and causing poor muscle tone and feeding issues in infancy, followed by relentless hunger (hyperphagia) and severe obesity in childhood, alongside developmental delays, learning disabilities, and distinctive behavioral problems. PWS is estimated to affect approximately 400,000 people worldwide and approximately 20,000 people in the United States, as per Rhythm.The company said that safety and tolerability profile of Setmelanotide therapy in the trial was consistent with the drug’s established clinical profile. In the United States, Setmelanotide is already indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to certain conditions including Bardet-Biedl syndrome.Rhythm is also looking to evaluate its experimental therapy RM-718 in PWS and expects the first patient with PWS to enter screening for this study in December.<h2 class="st-heading-2">Expert Take</h2>Bank of America subsequently raised its price target on Rhythm to $140 from $127 while keeping a ‘Buy’ rating on the shares. The firm, which is "encouraged" by the preliminary update, argues that a successful late-stage study in PWS would "offer an attractive commercial opportunity."<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around RYTM jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:586/59;" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAkoAAAA7CAYAAACEwqXUAAAQAElEQVR4Aex9DViUZfrvb/iQQRAGUpsxTaeshGw3zN2U7WOltT3CcjahL+HSvRJ1U6hzldY5tda1Vxf1v7akzpZoq2KXFpaluBsL7tEjXZ1W0TKxdMHv0cRmAmVQQQYZ4Nz3OzMwAzPDDPLtPdf7vO/zcd/38zw/3vfH/Xy8MwGt8hEEBAFBQBAQBAQBQUAQcItAAOQjCAgCgoAgIAgMGQSkI4JAzyIgjlLP4inWBAFBQBAQBAQBQWAIIdClo3T1ahNqay+jqqoGP/5YLUEwkHtA7gG/7gHmDuYQ5hJ33HkteWyTbXMdwk/Cz3IPyD3gzz3AvMH8wTzijYe8OkpswGy+hKCgIERFRUCnG4kxY0ZJEAzkHpB7wKd7gDmDuYM5hLmEOcUbIflTxrbYJtvmOrgu4SfhZ7kH5B7w5R5gvmDeYP5gHmE+8cQ/AZ4KLly4qBSNHh2N8PBQBAcHQaVSKXlyup4RkL4LAr4joFKpFO5gDmEuYU0Ht3C8u8Fhg22ybeGn7iIpeoLA9YmASuU7N7l1lNizCgwMgEYzQpyj6/Mekl4LAj2OgEqlUjiFuYU5prsVsC7bEH7qLoKiJwgIAs4IqLrgpk6OEq/VNTZeRWRkuLMdiQsCgoAg0CMIMLcwxzDX+GuQdViXbfirK/KCgCAgCHhDgHmF+YV5xlmuk6N05YoFYWHDZSbJGSWJCwKCQI8hoFKpFI5hrvHXKOsIP/mL2pCTlw4JAr2CgErlnps6OUrsSYWEBPdKI8SoICAICAKMAHMMcw3H/Qmsw7r+6IisICAICAK+IsD8wjzjLN/JUbJamxEUFOgsI3FBQBAQBLqPgBtN5hjmGjdFXrNYh3W9CkmhICAICALdRID5hXnGWb2To8SFKpW83cY4SBAEBIHeQUCl6j7HqFTd1+2d3ohVQUAQGCoIqFSd+cWtozRUOiz96BYCoiQICAKCgCAgCAgCdgTEUbIDIRdBQBAQBAQBQUAQGIoIXFufBoGj1Iyqs9WwXls/RVsQEAQEgSGMQCX2bNuLs0O4h9I1QaC/EOgxR6m+YjvWv7ca762i8P4WlJy40u0+HSnajD3VdvXab7CzoARf19rTvXWp3ov8omO9ZV3sCgKCQD8hULV7M1at3YEjLU4NOPMl1r+/uZ1nnIr6O2r9rhCrCstdmnFx3xZs+MLkkueaMOPH0ybUuGYO2pQ0XBAYSAj0jKPUcgjbd1zCnfMX45klFNLicHPo8G728xJqLjTCYrWra6Yh/X88gXiNPd1blxozahoae8u62BUEegWB1lagge7by5evwGy+jPPna8E/9GgyXYDRWE3hPH766QKqq83gn/24eLEOdXUN6Pj6a680boAYbW5sRFBrJQ4fam/Qke/PwILGdp5pL+r3WNDtOkSePoMjbS25hP8cNWO0XtuWIxFBYKAjMJS4qWccJSIiFxcj4lZMvMn+Z2wx47ttG7Hq/bVYtWYL9pyz5fOsUcnB3fhk7Vq899e1yN9jGy1x/rdmIoZtJK/M8BxD4fvb7aRB8Y9KsK9kC9asXIl3eJT4UzkKN7CN1S4jrvoTXyq2V61ai/Vkp56r5Vmjwv04XETtceg3UAHn7zwJ67l/UzsH5iiTWimHIKAg0NRkxaVL9Yrzc/XqVVy8eBmXL9eTw2RRHCB+tbWlpQVMVK10am5uAevwN87W1zeQbh34yo6TmZ41drRYTjHerdPAVwqKiEDN8UO2hrYcw5GqCIx2HsvVn0TJJ+vp+SfeySO+UQgDMO4mriEOWfX+enzyVaWyBcBdXs3B7dhAXLZqJc2ob/wSRsfs1bm9Nh5i/lPCZtsslof6lAaG3g59ZCUMp5UUecLHYLg4FvoJlHbwKbdp1UYUVriZuWc++2gvqkicD55Ry99tm6LneOHuQ/j7B8yZzLuVOPvVFqxftRLvvF+I7+z9hqMebrMTb7M9CYKAJwSYZ4YiN/WMoxQ6FQlTga/XrcWGov04e6kdxiNFW/Bt5MNY8vRCLJmtw/Fde3GRihsbqnHkTBRmZSzEM3NjYf22THGGJiUl487wCNw5m+STbmdJNNKI2eaINaKxuhJVNydiUVYWZo0+ie3/NOHuNLKx4BcI+v4bHCYN1OzFlh1mxFD+kiXz8curX6LkKBVYSf/0UdT8LB1L7Pr7DlBjR01D+v1jgZvuo3bS7NUokpVDEBhgCLADVFNzSXGQ6uqu2J2fJoSEDPO7pcOGDQM7TuwksbPEs1D15ESRX+W3rUGhMPpW6M1H8S0PjI4SB9w0FtFNjpabsWdrCWpinqTnfyEWTbOipOQYFZZj337gXuaup+fj0WljEQR3eUCILg6PEJctyVqMmZHl2FFKvIJqlPyrHDc8TFxGNh4eF4Jxv2F+8VQfVakcEbjz1uE4e6xSSTUeOomaCbdiEqWOFH2Cb0cQny4hm3+IQ/2ubdjTcb2NeY4Gr80kzwfPqDU22lIcP32mEQ/8gTiTeXdfIfaRvflLspA8zoRvv7Y5VEc88DbbkyAIdERgqHNTzzhKhJruV0/gmaeTMRlHUUijFdsM0RkYzgUiWm3EtwfK8O1ZK0LqTHAMlEZPiEUktyA6AmH8cMOXTwRunjhcEYwcEYZIfSzGBVMyLAQhLc1gOmg8cQaXaARpPUp1HvgejcNCUH3ONmOF4WNx27hAUgBYv7nRzYhMKR26J+nZ4EKgubmZltUuKUtqFottyODoATs73XGUAvi5cxihK8868bIcO0zsPFHWEDt0mHzrFRz/zxUcOWbGuBgaGDl62HCSZmwiENlMjhTx1HcNQVBXGWHEBOhvMmPfli9x2NiIIOYZt3lA2I2j0Hy6DCVFhTh4HrDxCrMR8dIIKJ/AwEZcqqG/n8f6FDHlFBkzASFnT1IbgCM/1GDC7TxoZD4Nw4Sf25fgwu7C3eMvwXCCbCpavp3CtOQk8t8/mngXOtx2d4SiGBYaArRym7meQI+8rQjLSRAgBK4XbuLHhbrbQ0eIFvck0WzN78ej/vvvYUAjrE3OtiNw27Q4jHPO6oW4hZYmXMzq7sIv74hyyZKEIDAYEOAltZ9+qqFlNff/DHmqOzg4yK+uBAUF0hKdYxOgq6qD+HivE48SXUsHd0p3961oPLYDhy+Ox+TxTn1ptMIFjQAtfj7tDkRjOH7+KM0kTQ2DYQct128rJ0Zzl0czRB+tx/YTIbjt/ofxoD7MblyLe+NC8N3Wzfj7ts34oup2mnkPATzWZ1fjS/StxJOVMNQcwnHTBNx2B2cynwZCHczx9mBtcn9vtEv4G+N6nHX6hreda5T4wEdggHFTrwLWM47Suf34f//hqWantgaHQI3xGDPqCuqD7sA9U+Js4e7xREBOcm6jVjS3uC3wKTNyrA4hV6yIvttRZxwm3xTSte411Nm1cZEQBHxHgJ2U6mozeJN2V1rs3AQG+v4oh9BSHc9EebN79WqTssRXT8tx3uQGVVl0LPRNlajX/ww654ZrxmJMSD2s0Xa+YK6K0SIEzTTQC0T0LVOR/IdpGP3DSRx3m1eJH800SHyYZrcjQlDf4HBcLuG78mbck/oIZjz0CObPexA6/jN5rM+5UVrE6JthKDmJqnG2ZTcofGqG4dgVm2DLGRiMIRgz1jYjZMuk843k4tWZUaXw2RVUna+nTH+O8d3kbX/qENnBisD1yE382F7730sTBet3m/HeyrXKZsj3/lkN/UPTiIxCcE/yw4j4bgNWbfw7tmxcjzVFx+CgEfcVE0HcEoTDBWTrk73de911fAKS7zRj+6qNyKeRnPIa8AX3tbXl0tS2vupLvPc+jQx5P1NbgUQEgb5FgJ2U8+fNyh4kX2pubPRvn1JwcDCY7LqyzRu8eTmutvZyV6KDpDwKDzw5D49Oi+rQ3rGYmRSLmn+txvpNhcjPW4v8vWagugxbPliPDVs4by/qf/YLTHaXh7HQjzJhZ95m5G/IR0XDcLv9CIwbXY99m4iHKKz6YDMKvzqJepJ3Wx9cP7pbx6L+rBFjiJtsJc58mo/1q3ag5s5EzFRmx6IQGVaJb78yAQG3Y/LNRpTwhu/3t6EqLNqm7vPZuR5fedtn4zZBOQ9KBK5XbuoZRynsViSkLcQzf0xHeto8PJOVjpkT7DM4YbcjeeFiLEpNwKw587Eo+XYaqYGmtLPw6M9h/9yFR597BI6kbsY8PLdoHhY9OY1mn5zLnOOALmEe5ifY1+vRoexXT2DJkifwOx7J0TX+BqpK9yDmZ9CojqJ8uOiHxuKRLGrnU/Mx6w4ulSAI9D0CvD+Il71aWlp9rryx8apfG7pbW5WpBp/tX7liUb5aoHWQ7vR2ec5DIhCmLF1pkZAxDwmOqaWbpiH96cVI/92DePSphUiPJ2dq1FQ8uWg+0mc9iEfmLcQfZmgBd3mIwj1PLsSix2bh0bnpSH403cZLLcdw8NxYPMIbr5+m8senQX1sN/YZCXp39VG2y0EDvkXPLcYjMU65bXyajHSym/4rapNSTM7egsWYp6RDMHn2YiyZ9wQyFhEXJz1haw/JuWDRkTOd+bStngQX3iYTclynCFzP3BTQo3/z4OGIpKlndzaDwhwE5a7UTV5ICPzbeeHGRkCIx/bA7SeQ/uFAPoJAvyDAy1z8Bpq/lfNG7JCQYERGhiMqKgIjR2owenQ0dLqRSuA453GZRjMCvFTnZx3KG3L8dQKD1Vnytb8hEREICXCVdsdd7vI66TbW0zLcFdTU8gZpoPmSEVXNURjt9J1wnXRcq/aY4vo7thMBgQhyant3bTtXyvXYHEvnXIlfbwhc79zk9Fhdb3966a8gMHAQ4FkbXubyp0XDh6sVp4gdooCAAISFhSI0NATDhgWDN2yrVCqoVColznlcxjoREeEYNSoK4eHDERgY4HOVPO3OzpLPCte7YGgcHk0dj6ovi/H3bYXY/l0QLf0lY3Lo9Q6M9H8wISDcBPjOkoPpL3u9t1X6P6gQ4P1C/jhJvBn7xhujoaHZIXaAutPZ4OAgRESE4cYbb6BruOJQwYcPO0v8hXI+iIoIIRB0YxxmzU7GIxz+21SMi6BMOQSBQYKAcJPtDyWOkg0HOQsC/YIAL2XV1FwEX7tqQADNGkVFjcANN0TSTFBgV+I+l4eHh9JSXRQtOw/zSYe/7JL3RfkkLEKCgCAwKBFgThpI3OQLiL3FTQG+VC4ygoAg0DsI8EwSj9q6sh4UFKgsl4WGqrsS7VZ5YGCg4oDx8p0vBszmy+C9Ub7IiowgIAgMPgSEm9r/ZuIotWMhMUGgTxFoaWmBxXK1yzp5eY33FAUG9v7jyhvCfXGWuO0NDZYu2y4C1ysC0u/BjAA/38JN7X/B3mfe9rokJggIAk4I8EzSjTdGK5uwnbJdouwk8VKbSqVyye/NRFfOUlBQEM0+aXBF1YTKi+d7syliWxAQBPoBAeEmV9DFUXLFQ1KCQJ8gwD89wt+XxIHfRuNX+Nkpcq6cZ5CioyN93mjtrOtvvKM8O0u87u6JFQAAEABJREFUadw5PyBApXwFQXjUcLy3rxAPvv8i3vhis7OIxAUBQWCQIyDc1PkP2GOOkuW8CSZTh1A7uKbmDauToBuXhNzTnYHyluPa91r42+uS53VU7zKUKJWUYNk4Sj9vS+FELuKjopD0gUkp9XTqbts92ZP83kXA8dMkDlLi303i7zmKjo5o26jNaXZOerclnq1zW3hvFEvwctyo0dH4l+EAEtb8L6wq/ScarU34P0cPwFDj/d5k/X4NltrO3GSi59TlB976tYU+VF7iygs+aCgi9r67UrEFtczVjkwfOUaxdzoXScRPSasNSlJOQw8B4abOf9MecpQMyJ1B/9x1HcKz9n/2neu15ZzIQawqFjknbMl+P9cZYKo0wOIXgXbsexRCVaGYQo5OrY8dUhytSqPdwbLAWEkO53lLu7bFKa7kujl1q+1u7EhWryPA09oWS6NLPQ0NjaiqqkFTUzNGjdLQ0lak8n1ILkJ9nFCpVIimGa3Ro6NgqK/C7A+z8UJRHqrqLra1pBWtWL23uC09ICM7M6HryE26+C4HRMXzVFDNGyh9c8MLvoBt73vmTmfhEmQyHs787AvHsAmrBQbiJ0MdJyQMNQSEm9z/RXvIUbIbn/Qn7DEaYXSEdxPsBR4uJgOGzLikre+nsOsFPcreScLyf3votz/ZEzOxp6EBRU9p/dHqUvbPf/4zHn/88S7lRKDnEeAvcHNnlV/H5Zkl/jHcjstw7uSd8yorK/HAAw8oy3SBgYF46aWXyOlqUkRqamowZ84cpUylUiE+Ph4srxR2ceIZpXX7dyCFnKTDJvdTrYUV+3ClydXx68JsvxSnbHTiJuMeZE7w1gwTDVi8lQ+hsl7iGAdCwjUOJAb+ta+5iRHZvn07Ro8eDRVx08SJE3Hw4EHO7jL0JTf1rKMUFAWtVtseNGqYPkzFLeNikbXdNiti+iCVlpmSkPfxMuiSc2kWpQLL79dRnm3pSVlCejgXpYULoAt2jOgsqHiP9DhNYKpiSNY+XaPIT38dBdsWINZeHvtiKUx7lyM+lPRJXje/GHZxgGv0YIsK2w7L9iyl3cucnJ2K/4qHLo7qtnWlTVaJtPVdj4SURGioHstlKB+ljeNIT0nRaSf1naavl7mM8ijf3dFxqrtyE9LH2fqlcjNzZdy+rA0H1367Gmfyio2NFWfJFZY+SXkiI0flTAAqlcqR7PJqtVrxwgsv4Ny5c9i7dy/+8Y9/4G9/+xvy8vIU3Y8++ghHjx7F/v37UVpaqsg988wzsPg4izBZO16x4+nES3D/93iZp+IBk6/WOHGTVgO1tRTLf0HcQ3yjDNgovSxGhykvbsL/ToxD1hcAPk4nbtLBttRkW/7KKqxAzv2h5HjG2mbDzxdjWRynVZRHsmsrSJEPm/yCtSXISdRRGZXriPuOmLBpnj0dHI+cIyxrDx5t2cuVC81iJ1C7U/JgUtJ0qivAAuKUpLVtOZTp49GRY6wVyEuxt4/uwyiyq6Ngw8Bus5r6HEP9oXKVbgGK2wnWLtB+Ea5px2Kgx/qamwwGAxYuXIjk5GQcO3YMN998M55++mlcvNg+a+0Ns77ipp51lM4fQPFnBShQQpnyEGvnrkCmtgK5S7JRZilB9pICWGYvR8b96chdOJ0w0CLl5Vzkvp2OWEqBl5B2ZiF+UTnS392KXS8noPbjVMTSNHHsG7twyrALfwrPwUOP20mC5ckpSn0RyNyUj8ypQMVb5NA8VoaENVuxYrYGpg8ysGI/G4d3WzYR5ayemYLE89TuTSVKGihD/rulqJ2eiAS1Pcv54uj7hzlInZuD2ol/QuZMuwC3sW1pjfIsRlrioxGrheJdHR2muotfTsemoEwUGYw49c1KpMfpoIHjQwT+bi3h4Oh3qtdZLSEwB259d716tQn86q23GsPDw7wVdyq7cOECvv76a2RkZODee+9FUlISfv/73+OTTz5BXV0d2Cn65ptvcM8992DatGn49a9/jQMHDsBsNney5S7jvgl3YrJ2gruitrx/VnzdFh+oEcNXDm4qQMkRevjU07H8tSRYiG+yPq6FafVSclpikflsCn773HKkaKkn0zKIm3KxdIaOEhaaZTIh97/HIleXjfxP85E+oYycrSTk1KVj6yEjytfHY8+ieCzbC/rY5PMWpaJ4ag62vpkCjakYC2L0yFYvx9aNmYizlmIZOWbUGsDqzRaZazv0SJ2th2lbHrZW2jIthXnIq9QjcRY32pbnfHbue8FnJTA4F1pdl9MqCJMF22Kx8ngDGo6vxBRaaoualW3HwKZY8VYOap/dau9THlJfLbUVeDgL13gAZgBl9wc37dmzR+GhJUuW4LbbbsOLL76IQ4cOKcEXaO7rI27qWUfJtAlZj6ciVQkrcEDpqR5Lado+5vTr5BxlIRdpyH+DHKSxcUi5X08SUZgyKwUpj8VBSynboaZ/9nuwYnEKEiYZkfd2MXD3MqyYG4tQdSyyFiUCO0vs9lkjBiu2r0PmY2lY+XIaZyBtVRGy56Zg6VMkCxPIr6B8gw+2SIyPoARk0hKa5YMClFgp4/BWbDKpkZGWQAk3h6kA2c9nIvPlbBScANThVGc3BnduLHfO4iXL84BuagaWzo1xKnfgQP1+ORNaWOgmdCp2ExUCcwNKL2Z19d0kgYEBCAkJ9qsFgbTUplar8eOPP7Z9wzdPZfNo7fLly8pMBsuw0QZaxv3pp5+g1+sxYsQIzvIpPPGz+73K7T5TjpbWVq8y/V1Y+paDm1KRVWhUmqOetQJ5c9QopgFZIs1Ex7y5Dhlj1YiZmYgpI0lEn0DcxDykpoT9mLYSez5dijTmrJ25eJ1WJNNey0Y8yUfNykTGhFoUf+XkiszNx67X0pDyQjaWTSIbk7NRtCYTKXOXIn0ypYmclNb4YovE+dA+lYUUlCJ/G5OMhQanxJEzMpA6lks7B+e+pz6eQ5qdZRw5htPU9smJSJyohnoiXamNFdATF7djEPPmLqwjfk55YTkytYCltmunW7gGA/rTH9x05swZjBw5EmPGjFGwGTVqlHKtqqpSrr6c+oKbetZRmrwCp4gsW5WQj0RHLydlYuksoGx/BeLezEFiuKPA01UP/ThHWQUO8GzQweWYwhsQOSwiUnAUd7wGdcxwTvtnK2bRUky35CJvO2DYXgCDOgPp9znbc4oT+e05a4TxrBmt5q1IOZKH1Gc3kaviJNMD0cR3d2HppBJk0ZJBaOgULPvCw5y3JgpRPVCfmOhZBJqa2Ov2bJN/tNZzqfuSG264ATNnzsTq1avx2GOP4dc0Y/TOO++4CttTxcXF2LVrFxYsWIDw8C4fRLsW8LuYXyJQ5ZkuGpqu4uQF5d99m85Ai6R93qo4ksxP5TQIsrVPg5RnM6E5XYYyawZWPseDN1uJx/NtepBvoBQbDu9RrpvSdPYN4w8hhxwnJbPTSQ21F37yy1Z4GjIXq1G6Jh8GawmKtgEJc5La2tWxaue+t7YWIa2jgFN6yv0JwOE85H5hgOEL4r/DQMqMeCcJ56gGUeQgOudIfHAi0B/cdPToUbdgHT9+3G2+u8y+4CbPzOeuRd3N+/dyLNseg4QZapS9mo1S7/8rOtQSgyk0osG0lTAqDpiD7PLR5oh10PCc9NPW2FRkzAA2fZaH4u0V0D6XgemejbeXaOKRwILHjTC25daitifeFNEkYEUZTYkbdyF7egVyEjKw6Rrs8iivvLwcn376aVtLJdJ7CDQ1NXk13vG7i7wK2wtVKhVycnLw+eefKyMznr5+5ZVXwF8MGRDQ/oh/Tctz7CA99dRTeOKJJ+zavl0i1WGIvfFmr8L/+emM1/KBWWhC3ss5sMxIQIw1D6938TUcHfugnxRHWWpklrS2OWGujhgV+3j4ayshLQNqcmgKPihGAbFhxhytjzV5F9M+lokUtRkFS+IRv6QM8evLkT9H7V3Jh1LhGh9A6keR/uCmO+64w22PeRnObYGbzL7gpnYWddMAv7Mc+3Q+K6CpYAo7K2Dhdfe5ubDMXYGijSuRUJuL9FfLbKaDQulagbyPy2Ay1UJZp6cc10OPlPlERnuXI/0tWls3mWA6TMSw3720q27HlG+2zI7vF4EW6QtTgM+yaOZGi4wUakdHk4601Ux94LaVYNOr6SQP6GcnQk/loRodnUuQ/3EFtZ1mmhZtonTHw4LatnrBc9lwTtqka1H86jIUHKZZJC05Y1PZbndwsFkT4rLh0Fdn/m20lpZWr9UFBwd5LfdUyEtrSUlJePfdd5GQkIDdu3dj0qRJiIyMVFQqKiqUN99+85vf4K233kJwcLCS78+pq42TR6rP+mOuz2Vd9+kUoKwSqP04Awu+iEH2ml3Ie0aDkkU08KDHS2mcms6f5WPTaZPnQc6MdGRoLMhdtICeS3r+aVm87LMS1z1AZManwxdbFhpwWezW7svE0gkVWP5sHizJ6UgJt+df48WwdjkK7l6Gom+MMFbswrqnYsBQXItZ4ZprQa/3dfuLm8aPH4/z588r2wa4l2b7vkneOsBpX0Nvc1OArw3xSc5lj1IqUp8vxldvpdMaPhHRq4lQj83AyjdiYPivVCzn5bSZS7FiGlDx6hSatk5FvoOgOlSmf64Eu57ToeTFh3ALL73dlYTln5fBwRcdxL0mvdnSz85AHCrw+twcOtvMqGl0lUk1WSZkIH2qLc/t+cjriFfa9hDS3zIg4c09OPBqjCKqnbMUGVoLihfFQheXA/1rf6J6lCLllDAnAxoaE6Yv4SXFBKQ/pSHnLB2ZtOQH54/VAoupGKl3RYG/qyn+rQYkrlmBtG4Q5IQJEyAzSc7g9n68paXFayVBQYFQqVReZTwV7tixA/yWG6/5v/HGG8ry2h//+Efw3qWDBw/it7/9raKamJiInTt3YsuWLeC35JRMH0+TRrWth7vVOF9/yW3+QMksddqjlPp4Klb8uwCZ84uhpkFc5kRg+mt5SFMXI33eJtRCj4xXM6C1bEK6Xgf9q6Vw+wlPxLrSdUisowHQXTrisVsw5dlclJ52K+0906utBDe8EIOs56eD315MmZOCa3VmHI3Tz0pHzN5liB2hgkplD8rbeg4J/67CNf7h1R/SfcNNZ9CRm/irSqKiorBq1Sr88MMP4C0Dd911Fzj4g0Nvc1MPOUp6LD3U6jL1zNPPrYeWYuZL5ZRfjqVERNzxGCV9CtnsdATFYGlpKxqqjTA37KKRGaB/wVWedQANEt6m/Aaz8h1N5oZWlL82XSGGTvLJ+VRfK/KTYft0TMOzLUxcigMNVEfpUthcHLR99HOJPNpSzhE3fW84ha0vTIcmyC7HBGhsgNloRkNDOVYszMYBWkZ0tFE9ax3Ml80wr0khBTUS15NctRl53AdqUznJKnsqgrRIWePAgWSajChaaGtpJxzseo46yLDLcfr0aVluc0Gk9xNdkZHzMpk/reFn7cSJE1i8eDH4n9Jf/vIX/PWvf0VyMt9AUMjn7NmzOHXqFJ1GyTsAAAUYSURBVObPn6/sY+K9TPzmmz/1jAqzzU550qlpqPNU1L/5dg5gnJxD/pMpyG8g/tmYqHAJNLZ06+dp0IBYJ3kdjA3EB9X07L7Na+mJyKdnsZXkqbj9mJSBIiPZqTbCWN2AVuNWpE3g4o7yehtPEi/yTDPQMU06Hm114AUSbT9SkJqsbk86x+x9d+WBRNd+2LlC4RjQgO7tFbC8sEvhWqOR+nRoBabTAC2n0ADmyDY+UurR2/rUEROlzHY6LVxjA2IAn/uLm/ilEp4F//DDD8GzS7w9YOXKlW0z4b5C1tvcFOBrQ3pTTj1SC42H59ylXrUGWq2Psi6KbhKebHG+0hgTyrblYtn9qci1JCL7+Rg3RvzJUkOj1XjezBmugSYcbR/1SI1nWTXj4KW8zYpEBhICLV0suwUEqLrVXJVKBX69tr6+HvxGG185rVLZ7G3YsEEZPDg7CRx3OFK+Vho93PtbcuYrl301NXjk+FkbqfapvcxjWh9luzLoyVYbL5woQS7NkMU/Wwr9S8vRnVll920oQ/HHtTCbagGNlvhWA1QcoBl2DeIn69yrSO6gR6C/uImBS0lJAXNWdXU1+GfQpk6dytl+hd7mpgHhKPmFSJ8JlyP/2WzkWxOx7hCNEIkv+qxqqWhIIhAaGoIxY0Z5DPxzIdfScd53xGv7fL0WO550fznudpz6n+s9hm3zXvGkKvk9jIBhZw6y362A/pUiHHgtrgetT0d28VLoC1OhU76wNxT6l03IKKjAulm+OYw92Bgx1UcI9Dc3MWeNHDmy7Xcu/e12b3OTOEoe/yIJWMGv+3+Tj4zJQhAeYZKCAYKANON6QkC/uAjGs+XY9Voi2pb4ewgAzYwVOGBubZuFbDi+Cytma3vIupgRBAYfAgGDr8nSYkFAEBAEBAFBQBAQBPoGAXGU+gbnTrVIhiAgCAgCgoAgIAgMfATEURr4fyNpoSAgCAgCgoAgMNARGLLtc+so8RsxQ7bH0jFBQBDodwSuhWOuRbffOy4NEAQEgQGNgDt+6eQo8ZfeWa3NA7oj0jhBQBAY3AgwxzDX+NsL1mFdf/VE3g0CkiUICAKdEGB+YZ5xLujkKA0bFozGxiZnGYkLAoKAINCjCDDHMNf4a5R1WNdfPZEXBAQBQcAXBJhfmGecZTs5SsOHq1Fff0V5NdRZUOKCgCDQrwgMmcp5aps5hrnG306xDuuyDX91RV4QEAQEAW8IMK8wvzDPOMt1cpTYkwoJGYaLF+uc5SQuCAgCgkCPIMDcwhzDXOOvQdZhXbbhr67ICwKCgCDgDQHmFeYX5hlnuU6OEhdqNCPQ3NyC2trLMrPEgHQniI4gIAi4IMCjNeYU5hbmGJdCPxKsyzbYFtv0Q1VEBQFBQBDohADzCPMJ8wrzS0cBt44SC91wg+0HMKuqalBX14CmJqs4TQyMBEFAEPAZASYg5g7mEOYSVnRwC8e7Gxw22Cbb5jq4ru7aEz1BQBDoGoGhJMF8wbzB/ME8wn1z8ArHnYNHR4mF2LOKioqA1WqF2XwJRuN5/PhjtQTBQO4BuQd8ugeYM5g7mEOYS5hTmFt6IrAttsm2uQ6uS/hJ+FnuAbkHfLkHmC+YN5g/mEeYTzzxkldHiZV4rY4NjB4d7fHHPL390KeUjRLcvPwQrNwfQ//+YO5gDmEuYU7pycA22TbXIfdSx3tJ0nJPyD3g7R5g3mD+YB7xxktdOkrelKVMEBAEBAFBQBAQBASBoYzA/wcAAP//QBVJ9QAAAAZJREFUAwAx8+yJL9i+RwAAAABJRU5ErkJggg==" width="586" height="59" alt="RYTM’s Sentiment Meter and Message Volume as of 12:46 p.m. ET on Dec. 11, 2025 | Source: Stocktwits"><figcaption>RYTM’s Sentiment Meter and Message Volume as of 12:46 p.m. ET on Dec. 11, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/RYTM">RYTM stock</a> has more than doubled this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/apollo-global-management-weighs-ipo-or-sale-of-invited-in-potential-deal-that-could-top-3-billion/cLIxS8NREnC">Apollo Global Management Weighs IPO Or Sale Of Invited In Potential Deal That Could Top $3B: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Rhythm Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder 

 The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management.

<ul class="summary-bullets"><li>In fiscal 2026, Toll Brothers expects to deliver 10,300 to 10,700 units at an average price of $970,000 to $990,000, it said.</li><li>CEO highlighted soft demand across many markets and added that the company continues to balance “price and pace.”</li></ul>Toll Brothers, Inc. (TOL) fell 4% in after-hours trading Monday as the luxury home builder missed fourth quarter earnings estimates and projected lower FY26 home deliveries in the face of muted housing demand.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/12/08/3201989/0/en/Toll-Brothers-Reports-FY-2025-Fourth-Quarter-Results.html">reported</a> net income of $446.7 million in the quarter ended Oct. 31, compared with $475.4 million in the corresponding quarter of 2024, and below an analyst estimate of $476 million. &nbsp;Adjusted earnings per share came in at $4.58, behind the $4.88 expected by analysts, according to data from Koyfin.Total revenues were $3.42 billion, compared to $3.33 billion in FY 2024’s fourth quarter, as the company delivered 3,443 homes, marginally higher than the 3,431 delivered in Q4 2024.<h2 class="st-heading-2">Outlook</h2>In fiscal 2026, Toll Brothers expects to deliver 10,300 to 10,700 units at an average price of $970,000 to $990,000, it said. In FY25, the company delivered 11,292 homes at an average price of $960,000.CEO Douglas C. Yearley, Jr. said that the company continued to execute well in FY2025 despite a choppy environment. “Our fourth quarter and full year results demonstrate that our luxury business is differentiated, as we serve a more affluent customer who is less impacted by affordability pressures,” he said. He also highlighted soft demand across many markets and added that the company continues to balance “price and pace,” while also managing spec starts and inventory on a community-by-community basis to best match local demand conditions.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/TOL">TOL stock</a> closed down 2% on Monday and fell 4% in after hours trading. On Stocktwits, retail sentiment around TOL jumped from bullish to extremely bullish territory over the past 24 hours, while message volume jumped from high to extremely high levels.A Stocktwits user attributed the drop in earnings to the sale of the company’s interests in approximately half of its Apartment Living portfolio, along with its operating platform, in September. The user expects a rally tomorrow on strong Q4 revenue.<stembedurl>https://stocktwits.com/profit_guru/message/638544129</stembedurl>TOL stock has gained 8% this year but fell about 13% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-greenlights-shipping-nvidia-h200-chips-to-china/cLIpcS9REmC">Trump Approves Nvidia H200 Shipments To China As Beijing Responds 'Positively’ — AMD And Intel Could Be Next</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A home site is listed as sold in a Toll Brothers housing development on December 4, 2012 in South Barrington, Illinois. (Photo by Scott Olson/Getty Images)

Toll Brothers Stock Slides After-Hours On Q4 Miss And Softer Delivery Forecast

Adjusted earnings per share for Q4 came in at $4.58, behind the $4.88 expected by analysts, according to data from Koyfin.

<ul class="summary-bullets"><li>Micron committed to supporting customers through the transition by providing continued warranty service and support for Crucial products.</li><li>Chief Business Officer Sumit Sadana said that the company made the decision to improve supply and support for its larger and strategic customers in faster-growing segments.</li><li>The company also said that it will deploy members from its Crucial team to existing open positions within the company to reduce the impact on its workforce.</li></ul> Micron Technology, Inc. (MU) said on Wednesday that it is exiting its Crucial consumer business, and halting the sale of the brand’s products at key retailers and distributors.The memory and storage solutions company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/12/03/3199169/14450/en/Micron-Announces-Exit-from-Crucial-Consumer-Business.html">said</a> that it will continue to ship Crucial products to consumers through the end of February 2026. It also committed to supporting customers through the transition by providing continued warranty service and support for Crucial products.<h2 class="st-heading-2">Rationale</h2>Micron’s Chief Business Officer Sumit Sadana said that the company made the decision to improve supply and support for its larger and strategic customers in faster-growing segments. Micron’s Crucial brand offers a wide range of memory and storage products worldwide, including an extensive range of memory options and internal and external SSDs up to 8TB.The company is now looking to improve long-term performance by concentrating on core enterprise and commercial segments, it said.The company also said that it will deploy members from its Crucial team to existing open positions within the company to reduce the impact on its workforce.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company dropped nearly 3% at the time of writing. On Stocktwits, retail sentiment around MU stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user termed the decision a “big mistake.”<stembedurl>https://stocktwits.com/BrooklynBoyTony/message/638052952</stembedurl>Another termed it a “smart move” highlighting that the company is now prioritizing higher margin product.<stembedurl>https://stocktwits.com/jhayes1/message/638049023</stembedurl><a href="https://stocktwits.com/symbol/MU">MU stock</a> has risen nearly 176% this year and by about 133% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-recalls-nearly-35000-units-of-its-delivery-vans/cLIXD62RE1s">Rivian Recalls Nearly 35,000 Units Of Its Delivery Vans Over Seat Belt Pretensioner Wear-out Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Micron Technology, Inc. is displayed on a smartphone screen.

Micron To Stop Selling Crucial Consumer Products As It Heightens Focus On Larger Customers

The company said that it will continue to ship Crucial products to consumers through the end of February 2026.

<ul class="summary-bullets"><li>Barclays noted that the company matched estimates on sales and beat on earnings, driven by continued strength at Hollister, with 15% comparable sales growth.</li><li>The firm said that it sees strong momentum for Abercrombie heading into the holiday season.</li><li>Morgan Stanley on Wednesday raised the firm's price target on Abercrombie &amp; Fitch to $95 from $78 and maintained an ‘Equal Weight’ rating.</li></ul>Abercrombie &amp; Fitch was one of the top-trending tickers on Stocktwits&nbsp;on Friday&nbsp;after Barclays raised the firm's price target, noting the company's third-quarter results this week showcased the continued strength of its Hollister brand.Barclays raised its price target on Abercrombie &amp; Fitch to $94 from $84 and maintained an ‘Equal Weight’ rating, according to TheFly. The firm noted that the company matched estimates on sales and beat on earnings, driven by continued strength from Hollister with 15% comp salesBarclay said that it sees strong momentum for Abercrombie heading into the holiday season.<h2 class="st-heading-2">Abercrombie’s Better-Than-Expected Q3 Results</h2>On Tuesday, the company’s third-quarter net sales rose 7% to $1.29 billion, compared with Wall Street estimates of $1.28 billion, according to data from Fiscal AI. Abercrombie’s quarterly adjusted earnings per share came in at $2.36, compared with expectations of $2.17.Abercrombie also raised the lower end of its annual net sales and profit forecasts heading into the holiday season, betting on growing demand for its namesake brand and Hollister’s products.<h2 class="st-heading-2">Analysts’ Take</h2>Morgan Stanley on Wednesday raised the firm's price target on Abercrombie &amp; Fitch to $95 from $78 and maintained an ‘Equal Weight’ rating. The third-quarter beat "surprised to the upside,” and the firm leaves the report more constructive as Abercrombie’s financial profile "may be structurally better than we thought," Morgan Stanley said.UBS analysts noted that Abercrombie's results and improved guidance highlight its strong fundamentals and noted that the firm sees potential for an earnings per share (EPS) compound annual growth rate of 14% following FY25.Retail sentiment on Abercrombie remained unchanged in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/ANF">Shares of Abercrombie</a> have declined by over 36% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/from-walmart-to-best-buy-retailers-see-a-solid-start-to-holiday-quarter/cL5aGzmRELI">From Walmart To Best Buy, Retailers See A Solid Start To Holiday Quarter – But Consumers Are Waiting For Discounts</a>

General view of the Abercrombie and Fitch store in Carnaby Street.

Abercrombie & Fitch Catches Retail Attention After Barclays Raises Price Target On Hollister Momentum

Barclays raised its price target on Abercrombie & Fitch to $94 from $84 and maintained an ‘Equal Weight’ rating, according to TheFly.

<ul class="summary-bullets"><li>The company sees annual earnings per share between $10.20 and $10.50, up from the previously estimated $10.00 to $10.50.</li><li>Abercrombie’s third-quarter net sales rose 7% to $1.29 billion, compared with Wall Street estimates of $1.28 billion, according to data from Fiscal AI.</li><li>Telsey Advisory Group analyst Dana Telsey said the Abercrombie &amp; Fitch brand continues to face difficult comparisons, but the third-quarter results reflect some sequential improvement.</li></ul>Abercrombie &amp; Fitch (ANF) shares jumped 27% in early trading on Tuesday after the apparel maker raised the lower end of its annual net sales and profit forecasts heading into the holiday season and betting on growing demand for its namesake brand as well as Hollister’s products.“Hollister brands grew 16% on a strong finish to back-to-school and fall seasonal transition,” CEO Fran Horowitz said, adding that Abercrombie brands made sequential progress in line with the company’s expectations.“We are tightly managing inventory as we aim for fourth quarter brand net sales to be approximately flat to last year’s record,” Horowitz said.Abercrombie now expects net sales to grow in the range of 6% to 7% for fiscal year 2025, compared with the prior forecast of 5% to 7% rise. The company sees annual earnings per share between $10.20 and $10.50, compared to the $10.00 to $10.50 previously estimated.<h2 class="st-heading-2">Abercrombie’s Partnership Bolsters Growth</h2>The company in August said that its namesake brand announced a multi-season partnership with NFL Pittsburgh Steelers linebacker TJ Watt and his wife, former professional soccer player Dani Watt.The first release of the co-designed collection for Abercrombie’s activewear brand, Your Personal Best (YPB), was made available in August. This has helped the company attract new customers to its stores.Telsey Advisory Group analyst Dana Telsey said that the Abercrombie &amp; Fitch brand continues to face difficult comparisons, but the third-quarter result reflects some sequential improvement, and the outlook for flat sales at the brand in the fourth quarter is encouraging.<h2 class="st-heading-2">Abercrombie’s Q3 Results</h2>The company’s third-quarter net sales rose 7% to $1.29 billion, compared with Wall Street estimates of $1.28 billion, according to data from Fiscal AI.Abercrombie’s quarterly adjusted earnings per share came in at $2.36, compared with expectations of $2.17.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Abercrombie &amp; Fitch was one of the top-trending tickers on Stocktwits. Retail sentiment on the stock jumped to ‘extremely bullish’ from ‘neutral’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/ANF">Shares of Abercrombie</a> have declined by over 44% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dicks-sporting-goods-restructures-foot-locker-business-with-some-store-closures-inventory-cleanup/cL520eLREXM">Dick’s Sporting Goods Restructures Foot Locker Business With Some Store Closures, Inventory Cleanup</a>

Abercrombie & Fitch store in Munich, Germany. | Source: Wikimedia Commons

Why Is ANF Stock Soaring Before The Bell Today?

Abercrombie now expects net sales to grow in the range of 6% to 7% for fiscal year 2025, compared with the prior forecast of 5% to 7% rise.

<ul class="summary-bullets"><li>UBS said that it believes Micron's cycle will be more durable this time as high-bandwidth memory "crowds out" the traditional memory market.</li><li>The firm added that most, if not all, of the industry's capacity additions through 2027 will likely be directed toward high-bandwidth memory.</li><li>Retail sentiment on Micron remained unchanged in the ‘bullish’ territory, with message volumes at ‘high’ levels, according to data from Stocktwits.</li></ul>Micron Technology (MU) became the top trending ticker on Stocktwits after UBS raised its price target on the stock to $275 from $245 and noted that the company is likely tracking above the high end of its guidance.UBS maintained a ‘Buy’ rating on the shares, according to TheFly. The firm said that its recent channel checks indicate "tight" supply conditions persist. Shares of Micron were down nearly 9% in early trading on Thursday.Despite the lack of a positive preannouncement, Micron is likely tracking above the high end of its guidance with double data rate five contract negotiations now edging toward up 20% quarter-over-quarter or higher, UBS noted.UBS said that it believes Micron's cycle will be more durable this time as high-bandwidth memory "crowds out" the traditional memory market. Most, if not all, of the industry's capacity additions through 2027 will likely go to high-bandwidth memory, the firm added.<h2 class="st-heading-2">Semiconductor Tariffs</h2>On Wednesday, according to a Reuters report, U.S. officials are privately saying that they might not levy the long-promised semiconductor tariffs soon. The report, citing people with knowledge of the matter, noted that officials relayed these messages over the last several days to stakeholders in the government and private industry.The report added that the Trump administration is trying not to provoke China and is taking a cautious stance. The news comes as a heave of relief for several companies in the space, including AMD (AMD), Intel (INTC), Marvell (MRVL), Micron (MU) and Nvidia (NVDA), among others.<h2 class="st-heading-2">What Is Retail Thinking?</h2>Retail sentiment around Micron remained unchanged in the ‘bullish’ territory, with message volumes at ‘high’ levels, according to data from Stocktwits.A user on Stocktwits noted that Micron has signed contracts for years with significant growth and revenue, adding that UBS’ $275 price target “is very conservative.”<stembedurl>https://stocktwits.com/84Hawk/message/636918185</stembedurl><a href="https://stocktwits.com/symbol/MU">Shares of Micron</a> have gained over 150% this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/bbwi-stock-cracks-premarket-ceo-warns-of-softer-q3/cLPAKD6REa5">BBWI Stock Cracks After CEO Warns Of Tough Holiday Quarter, Slashes Full-Year Guidance</a>

 The logo for Micron Technology is posted at their headquarters on June 25, 2025 in San Jose, California. 

Micron Stock Draws Investor Attention Following A Price Target Boost From UBS 

UBS maintained a ‘Buy’ rating on the shares and noted that its recent channel checks indicate "tight" supply conditions persist.

<ul class="summary-bullets"><li>The company said that the late-stage study of Mitapivat in patients with sickle cell disease met the primary endpoint of hemoglobin response.&nbsp;</li><li>The drug also yielded positive outcomes on change from baseline in hemoglobin concentration and indirect bilirubin levels compared with placebo.&nbsp;</li><li>While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises compared to placebo, this trend did not achieve statistical significance, the company noted.</li></ul>Shares of Agios Pharmaceuticals, Inc. (AGIO) slumped 48% on Wednesday after the company reported mixed results from its drug trial in sickle cell disease.Sickle cell disease is an inherited blood disorder where red blood cells become rigid, sickle-shaped, and unable to flow easily through blood vessels, causing pain and organ damage. The condition leads to complications like painful episodes or crises, anemia, infections, stroke, and damage to organs.<h2 class="st-heading-2">What Did The Study Show?</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/19/3190791/31990/en/Agios-Announces-Topline-Results-from-RISE-UP-Phase-3-Trial-of-Mitapivat-in-Sickle-Cell-Disease.html">said</a> that the late-stage study of Mitapivat in patients aged 16 years and older with sickle cell disease met the primary endpoint of hemoglobin response, with the drug demonstrating a statistically significant improvement compared to placebo. Hemoglobin response is defined as an increase from baseline in average hemoglobin by more than or equal to 1.0 g/dL.The drug also showed positive effects on changes from baseline in hemoglobin concentration and indirect bilirubin levels compared with placebo.While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) or acute pain needing medical contact compared to placebo, this trend did not achieve statistical significance, the company noted. Further, there were no improvements from baseline on fatigue scores among patients, the company noted.The firm now expects to share the comprehensive results from the clinical program with the FDA in the first quarter of 2026 and seek potential U.S. regulatory approval.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AGIO">AGIO stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.AGIO stock is down by 28% this year and by 57% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/kzia-stock-soars-after-company-stage-iv-cancer-patients-shows-initial-complete-remission-on-its-drug-combination/cLPoQdMREBN">KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Agios Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial 

 Sickle cell disease is an inherited blood disorder where red blood cells become rigid, sickle-shaped, and unable to flow easily through blood vessels, causing pain and organ damage.

<ul class="summary-bullets"><li>Olema’s lead product candidate, Palazestrant, belongs to the same class of drugs as Roche’s and is being studied in breast cancer.&nbsp;</li><li>Oppenheimer raised its price target on Olema Oncology to $45 from $22 and kept an ‘Outperform’ rating on the shares.&nbsp;</li><li>The analyst’s new price target implies about a 428% upside from the stock’s Monday closing price.</li></ul>Shares of Olema Pharmaceuticals Inc. (OLMA) more than doubled Tuesday morning on the heels of Roche announcing positive results from its late-stage trial in breast cancer.Roche was <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.roche.com/media/releases/med-cor-2025-11-18">evaluating</a> Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer. In the study, Giredestrant treatment showed a statistically significant and clinically meaningful improvement in invasive disease-free survival compared with standard-of-care endocrine therapy.Giredestrant is an investigational, oral, selective oestrogen receptor degrader or SERD. According to Roche, this is the first late-stage study of a SERD to demonstrate a significant benefit in the adjuvant setting.<h2 class="st-heading-2">Expert Take</h2>As per Oppenheimer, Olema shares were trading pre-market on news that Roche's (RHHBY) trial met its primary endpoint. The analyst subsequently raised its price target on Olema Oncology to $45 from $22 and kept an ‘Outperform’ rating on the shares.The analyst’s new price target implies about a 428% upside from the stock’s Monday closing price.Oppenheimer said it was not expecting this readout, as the entire narrative has been around Roche's different breast cancer clinical trials. Nonetheless, the data are a welcome surprise, it added.Early breast cancer is a multi-billion-dollar market, and one that the firm did not have in its model. These data also incrementally derisk another Roche drug trial, which is testing oral SERDS against aromatase inhibitors in the frontline metastatic setting, Oppenheimer added.Olema’s lead product candidate, Palazestrant, is also a SERD being investigated in patients with recurrent, locally advanced, or metastatic forms of breast cancer. It is being evaluated as a single agent in a late-stage trial and in combination with ribociclib in another late-stage trial.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OLMA">OLMA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:622/59;" src="data:image/png;base64,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" width="622" height="59" alt="OLMA's Sentiment Meter and Message Volume as of 9:46 a.m. ET on Nov. 18, 2025 | Source: Stocktwits"><figcaption>OLMA's Sentiment Meter and Message Volume as of 9:46 a.m. ET on Nov. 18, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed pessimism about the stock, noting that the hype had passed by pre-market hours, when the stock was up over 200%.<stembedurl>https://stocktwits.com/ChannelRed/message/636586904</stembedurl>Another user, however, believes the stock will touch $100.<stembedurl>https://stocktwits.com/murphylaw/message/636586451</stembedurl>OLMA stock is up by 233% this year and by 125% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/zymeworks-shifts-to-royalty-driven-model-approves-125-m-buyback-plan/cLPVdKtRE7F">Zymeworks Shifts To Royalty-Driven Model From Licensed Drugs, Approves $125M Buyback Plan</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.

In this photo illustration, the Scholar Rock Holding logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did Scholar Rock Soar 26% Today?

The company is planning to reapply for approval of a muscle atrophy therapy in the coming year. 

VFMO
Vanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VFMO News

VFMOVanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF